New AMA Chief: No Chaos with Court's Health Ruling

Source: Associated Press, Lindsey Tanner (6/6/12)

"The AMA has supported Obama's health overhaul, though a vocal contingent of doctor-members has urged the group to back off that stance."

Associated Press, Lindsey Tanner

Americans should not expect chaos if the U.S. Supreme Court rejects all or part of the sweeping healthcare law, the incoming president of the nation's largest physicians group said Wednesday.

Dr. Jeremy Lazarus, who takes over as the American Medical Association's president later this month, isn't making any predictions on a high court decision, he told The Associated Press in an interview.

His preference would be for the court to uphold President Barack Obama's health overhaul. But if it doesn't, "I don't see doctors just throwing up their hands or patients not being able to get taken care of," Lazarus said.

Health insurance coverage "and how that influences the cost of healthcare, and whether everyone gets a fair shot at getting coverage—those will be challenges. But I don't think it will be chaotic," Lazarus said.

Lazarus, 68, a Denver psychiatrist, takes over at the AMA on June 19 during the group's annual policymaking meeting in Chicago. He'll be just the third psychiatrist to lead the AMA, and the first in decades. . .View Full Article

Novavax Shares Shoot 65% Higher on Phase 3 COVID-19 Vaccine Trial's 89.3% Effectiveness
Source: Streetwise Reports (01/29/2021)

Novavax Inc. shares established a new 52-week high after the firm's COVID-19 vaccine demonstrated an 89.3% efficacy rate in a Phase 3 trial in the U.K. and also showed efficacy against the South African variant in a Phase 2b trial.

Abiomed Shares Gain 8% After Firm Announces Record Q3 Revenue of $232 Million
Source: Streetwise Reports (01/28/2021)

Shares of cardiac medical device maker Abiomed Inc. traded higher after the company reported record revenue for Q3/21 despite the impact from COVID-19.

Sorrento Shares Rise 35% After Firm Posts Positive Data from Phase 1b ICU COVID-19 Trial
Source: Streetwise Reports (01/27/2021)

Shares of Sorrento Therapeutics traded higher after the company released positive preliminary results from it of Phase 1b COVI-MSC™ Study for treatment of hospitalized ICU COVID-19 patients.

Life Sciences Co. Receives Large Livestock Feed Order from New Client in Mexico
Source: Streetwise Reports (01/27/2021)

Avivagen Inc. reported it has secured a six tonne order for OxC-beta™ Livestock from a new customer in Queretaro City, Mexico.

Coverage Initiated on Biotech 'Improving Drugs Via Prodrug'
Source: Streetwise Reports (01/27/2021)

KemPharm's key near-term catalyst, lead value driver and other pipeline drug candidates are discussed in a ROTH Capital Partners report.

Vir Shares Climb 48% on Initial Phase 1 Chronic Hepatitis B Trial Data
Source: Streetwise Reports (01/26/2021)

Vir Biotechnology shares traded higher after the company reported data from its Phase 1 Chronic Hepatitis B Study that showed VIR-3434 significantly and rapidly reduced hepatitis B surface antigen.

Aurinia Pharma Shares Open at 52-Week High as FDA Approves Adult Lupus Nephritis Drug
Source: Streetwise Reports (01/25/2021)

Shares of Aurinia Pharmaceuticals traded 30% higher after the company reported that the U.S. Food and Drug Administration approved its LUPKYNIS™ (voclosporin) for use in treating adults with active lupus nephritis.

AzurRx Doses First Two People in Expanded Phase 2b Trial of Cystic Fibrosis Patients
Source: Streetwise Reports (01/22/2021)

AzurRx BioPharma shares traded 45% higher after the firm advised it had dosed the first two patients in its Phase 2b OPTION 2 Extension Study of MS1819 for treatment of exocrine pancreatic insufficiency in patients with cystic fibrosis.

Imagin Medical Is Bringing Cystoscopy into the 21st Century
Source: Dr. KSS, MD, PhD, for Streetwise Reports (01/21/2021)

Dr. KSS, MD, PhD, editor-in-chief of PubBio.co, profiles a small cap that "is poised to bring to clinic a next-generation of must-have cystoscopy equipment."

A Solace to the Stress of the SolarWinds Hack
Source: Jack Hurley for Streetwise Reports (01/21/2021)

Against the backdrop of the massive SolarWinds hack, value investor Jack Hurley discusses his investment thesis for Leonovus Inc, whose products provide an "ironclad level of cybersecurity."